Allergy

ImmunoLytics: Plan Ahead for Spring Allergy Season

Retrieved on: 
Thursday, February 29, 2024
HVAC, Growth, HEPA, Health, Allergy, Spore, EPA, Wheeze, IEP, Pollen, Nose, Water, Cough

Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.

Key Points: 
  • Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.
  • If allergy sufferers also have mold sensitivity, that will exacerbate the situation.
  • To better prepare for the upcoming spring allergy season, people should test their homes to see if there is a mold issue.
  • ImmunoLytics Mold Check-Up™ costs $36 per room and is analyzed by the company’s lab team that looks for 37,000 species of mold.

FSIS ISSUES PUBLIC HEALTH ALERT FOR NURTURE LIFE READY-TO-EAT CHICKEN MEAL PRODUCT DUE TO MISBRANDING AND AN UNDECLARED ALLERGEN

Retrieved on: 
Wednesday, February 28, 2024
Allergy, Food safety, Poultry, KIDS, Office for Civil Rights, Meat, Entrepreneurship, Egg white, Human, Independence Avenue, Civil and political rights, PARM, FSIS, USDA, TDD

WASHINGTON, Feb. 27, 2024 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for Nurture Life’s Chicken Parm with Super Veggie Spaghetti meal products due to misbranding and an undeclared allergen.

Key Points: 
  • WASHINGTON, Feb. 27, 2024 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for Nurture Life’s Chicken Parm with Super Veggie Spaghetti meal products due to misbranding and an undeclared allergen.
  • FSIS is issuing this public health alert to ensure that consumers with an allergy to egg are aware that this product should not be consumed.
  • The following product is subject to the public health alert [ view labels ]:
    5.9-oz.
  • Consumers with questions about this public health alert can contact Jennifer Chow, Co-Founder, Nurture Life, Inc., at 312-517-1888 or email at [email protected].

Imprivata launches new Biometric Patient Identity solution to protect patient privacy and address misidentification crisis

Retrieved on: 
Tuesday, February 27, 2024
Cloud, Name, Epic Systems, Medicine, Fraud, EHR, Approximation error, Communication, Risk, Identity theft, Health care, HIPAA, City, Medical error, Allergy, Organization, Patient, Privacy, Facial recognition, Research, Nursing

WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Imprivata , the digital identity company for life- and mission-critical industries, today announced the availability of Imprivata Biometric Patient Identity , a first-of-its-kind facial recognition solution developed for the unique privacy needs of healthcare organizations to ensure accurate and efficient patient identification.

Key Points: 
  • WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Imprivata , the digital identity company for life- and mission-critical industries, today announced the availability of Imprivata Biometric Patient Identity , a first-of-its-kind facial recognition solution developed for the unique privacy needs of healthcare organizations to ensure accurate and efficient patient identification.
  • The solution comes at a critical time when patient misidentification presents a growing problem in the U.S., as research shows that 24% of an organization’s healthcare records were duplicates.
  • Designed with HIPAA compliance in mind, the solution solely uses biometric data for approved purposes, ensuring patient data stays as private as the patient’s health record.
  • Imprivata invites healthcare professionals and organizations to discover more about Imprivata Biometric Patient Identity and embrace the future of patient safety with confidence.

Early warm weather leads to early pollen count, Western Maryland health system allergy specialist says

Retrieved on: 
Monday, February 26, 2024
Snow, Patient, Tree, Weather, Pollen, Nose, Allergy, Environment

Paul Mauriello, M.D., with Meritus Allergy & Asthma Specialists said he found tree pollen when checking his air sampler on Feb. 12.

Key Points: 
  • Paul Mauriello, M.D., with Meritus Allergy & Asthma Specialists said he found tree pollen when checking his air sampler on Feb. 12.
  • “It’s a couple weeks early, by my records.”
    The reason for the early pollen count has to do with the environment, he said.
  • “Just a few nights of warmer weather, you'll have enough to get going.”
    Fortunately for allergy sufferers, the snow that fell in the following days cooled off the pollen production.
  • Meritus Allergy & Asthma Specialists sees the majority of its patients related to spring pollen, Dr. Mauriello said.

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 26, 2024
AAAAI, Injection, KIT, Research, Dermatology, Omalizumab, Eosinophilic esophagitis, B cell, Hypersensitivity, Quality of life, Work, Prurigo nodularis, Loss, DLQI, ILT4, Data, PD-1, Contingency, Inflammation, Cell, Myelocyte, Rockefeller University, Therapy, PN, Allergy, WCI, UAS7, Patient, Dermatology Life Quality Index, CSU, Survival, Congress, Disease, G&A, Itch, SRS, American Academy, Pharmaceutical industry

HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
  • Celldex is currently planning for the initiation of a Phase 2 subcutaneous study in prurigo nodularis (PN) in early 2024.
  • The litigation settlement related loss had a ($0.26) impact on net loss per share for the twelve months ended December 31, 2023.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

Retrieved on: 
Monday, February 26, 2024
SAN, Incidence, The Study, AAAAI, Caregiver, Angioedema, Histamine, Principal, ARS, FDA, Quality of life, Anaphylaxis, Body surface area, Data, Convention center, Skin, Safety, Joint task force, Allergy, Patient, Flare, Data analysis, CSU, Erythema, Pediatrics, Asthma, Adrenaline, Itch, American Academy, Pharmaceutical industry

Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.

Key Points: 
  • Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.
  • “Urticaria is not only a standalone type I allergy disease, but also represents the most frequent symptom observed during type I allergic reactions including anaphylaxis.
  • neffy may provide episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients.
  • This would follow the anticipated FDA approval of neffy for allergic reactions (Type I) including anaphylaxis in the second half of 2024.

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Retrieved on: 
Monday, February 26, 2024
Therapy, Allergy, SAN, AAAAI, Macrophage, Food allergy, Inflammation, B cell, Immunoglobulin E, Prurigo nodularis, MRGPRX2, Skin, Annual general meeting, Prurigo, ADCP, Patient, Poster, Abstract, American Academy, Vaccine

SAN CARLOS, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced a poster presentation at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The poster highlights preclinical data detailing AK006’s mechanism of action and ability to reduce MRGPRX2-induced skin inflammation.

Key Points: 
  • The poster highlights preclinical data detailing AK006’s mechanism of action and ability to reduce MRGPRX2-induced skin inflammation.
  • Inappropriate mast cell activation, via IgE-dependent and IgE-independent pathways, has been implicated in the pathogenesis of multiple inflammatory skin diseases.
  • IgE-dependent mast cell activation has been identified as a pathogenic driver of chronic spontaneous urticaria and food allergy and agents which target this pathway have demonstrated therapeutic activity.
  • More recently, mast cell activation through MRGPRX2, an IgE independent mast cell activation pathway, has been implicated in the pathogenesis of chronic spontaneous urticaria, atopic dermatitis and prurigo nodularis.

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Retrieved on: 
Friday, February 23, 2024
Translational medicine, Senior, AAAAI, Mouse, Research, DIA, Animal, Asthma, Anaphylaxis, Eosinophilic bronchitis, Antibody, Allergy, Neutrophil, Therapy, PSA, CD117, CSU, American Academy

The two poster presentations cover separate studies that evaluated briquilimab in Mrgprb2-mediated drug-induced anaphylaxis (DIA) and passive systemic anaphylaxis (PSA).

Key Points: 
  • The two poster presentations cover separate studies that evaluated briquilimab in Mrgprb2-mediated drug-induced anaphylaxis (DIA) and passive systemic anaphylaxis (PSA).
  • Results from both studies demonstrated that a single dose of briquilimab protected against anaphylaxis, as measured by significantly higher core body temperatures in animals treated with briquilimab vs. untreated animals.
  • The oral presentation covers a study that evaluated briquilimab in allergic asthma, which demonstrated that a single dose of briquilimab significantly reduced the numbers of lung mast cells and bronchoalveolar lavage-recovered eosinophils.
  • Additionally, airway-infiltrated eosinophils and neutrophils, as well as airway hyper-responsiveness, decreased in briquilimab-treated mice, suggesting briquilimab has the potential to prevent allergic asthma via mast cell depletion.

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

Retrieved on: 
Thursday, February 22, 2024
SAN, Caregiver, ARS, Anaphylaxis, Event, Allergy, Webcast, Patient, Adrenaline

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that it will host a virtual investor day highlighting neffy® (epinephrine nasal spray) on Thursday, March 7, 2024, at 1:00 p.m.

Key Points: 
  • SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that it will host a virtual investor day highlighting neffy® (epinephrine nasal spray) on Thursday, March 7, 2024, at 1:00 p.m.
  • The event will include presentations by members of the ARS management team and by two distinguished allergists:
    A live question and answer session will follow the formal presentations.
  • The neffy Investor Day webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors & Media section of the Company's website.
  • A replay of the webcast will be archived on the Company’s website for 90 days.

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Retrieved on: 
Tuesday, February 20, 2024
Allergy, Epinephrine autoinjector, SAN, EMA, PD, Caregiver, Committee, CRL, Doctor of Philosophy, RN, ARS, Absorption, FDA, Food, File, Anaphylaxis, Heart rate, NAC, PDUFA, Agency, Entrepreneurship, Complete Response Letter, FARE, Symantec Endpoint Protection, Safety, Health, Lower respiratory tract infection, University, Rhinitis, Nasal mucosa, CHMP, European Medicines Agency, Nitrosamine, Patient, Pediatrics, IM, Adrenaline, Translational research, Trial of the century, Pharmaceutical industry

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced topline results from its clinical study comparing repeat doses of neffy (epinephrine nasal spray) to repeat doses of epinephrine intramuscular (IM) injection, as requested by the FDA with and without nasal allergen challenge (NAC) conditions.

Key Points: 
  • “The study objective was to compare twice dosing with epinephrine injection and twice dosing with neffy under normal conditions and after nasal allergen challenge.
  • With these results, we are completing the necessary work to submit our response to FDA in the next couple of months.
  • The repeat dose study under NAC conditions was designed with the FDA to address the Agency’s outstanding questions regarding neffy as described in the Complete Response Letter (CRL) from September 2023.
  • In addition, multiple PADAC members highlighted the favorable profile of neffy in our single dose NAC study.